



	Questions : Lok Sabha




























Screen Reader Access
Skip to Main Content
Skip to Navigation



Text Size

                                A

                                A
A















हिन्दी मे








Parliament of India Lok Sabha House of the
                        People






* Special Characters not allowed












India Time 


Your Time 


                        Monday,
                        11 April 2022









HomeMembersSitting MembersMembers Home PageMembers' PortalContact DetailsMembers SearchStatistical AnalysisAttendance of MembersHandbook Members Since 1952Digitized Who's WhoOthers BusinessProvisional CalendarList of BusinessPapers to be LaidList of Private Members' BusinessBulletin-IDigitized Lok Sabha Bulletin Part IBulletin-IIStatement of WorkSpecial Mentions (ZERO HOUR)Resume of WorkDigitized Resume of Work done by Lok Sabha QuestionsHomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions DebatesIntroductionSynopsisUncorrected DebateText of DebateDigitized DebatesConstituent Assembly DebatesWit And HumourDebate SearchHindi FontsDisclaimer Papers LaidPapers Laid on the Table of the House LegislationIntroduction(How Bill Becomes Act)Bills IntroducedBills PassedBills PendingBills AssentedBills LapsedBills WithdrawnBills NegativedBills Search Disclaimer CommitteesIntroductionChairpersonSummary of WorkCommittee Meetings ScheduleBills Referred to CommitteesReports PresentedDigitized ReportsPress ReleaseMembership SearchToday's Committee MeetingsCommittee Subject SelectedDepartment Related-RS Govt. AssurancesSANSAD TVIntranet





HomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions











Download as PDF




Print












PDF/WORD(Hindi)


PDF/WORD




                                    GOVERNMENT OF INDIA
                                





                                    MINISTRY OF
                                    HEALTH AND FAMILY WELFARE






                                    LOK SABHA
                                





UNSTARRED 


                                    QUESTION NO:
                                

996






                                    ANSWERED ON: 
                                

18.09.2020






Use of Drugs under Clinical Trial for COVID-19




Margani Bharat














                        Will the Minister of





HEALTH AND FAMILY WELFARE


                        be pleased to state:-















                                                    Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:(a) whether the Government has permitted the use of drugs under the clinical trials for treating COVID-19, rare genetic diseases and paediatric disorders without amending New Drugs and Clinical Trial Rules;(b) if so, the details thereof and the drugs that the Government is likely to permit to use under the above exemption; and(c) whether Government is aware of the countries using drugs under clinical trial for COVID-19; and(d) if so, the details thereof and the drugs likely to be imported by the Government in this regard?






ANSWER




                                                        ANSWERTHE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE(SHRI ASHWINI KUMAR CHOUBEY)(a): Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health & Family Welfare grants permission to import/manufacture new drugs under the provisions of New Drugs and Clinical Trial Rules, 2019. No permission for manufacture/import of any new drug for treatment of COVID-19, rare genetic diseases and pediatric disorder, for which there is no provision in the existing New Drugs & Clinical Trial Rules, 2019, has been granted by CDSCO.(b): Does not arise.(c) & (d): As per information available in public domain, various drugs are under clinical trial for COVID-19 and are being used for treatment of COVID-19 patients by other countries.        However, CDSCO has approved manufacture/marketing of the following three drugs for Restricted Emergency Use in the country for treatment of COVID-19 infection:a.	Remdesivir Injectable formulations,b.	Favipiravir tablets, and c.	Itolizumab injection.
























HomeArchiveIndex to Select Questions (1984-1999)Ballot ListStatistical Statements Relating to QuestionsUploading of Questions - Status QueryProcedure for Sending Text of Questions & AnswersDemarcation of responsibilities in Govt. of IndiaBrochure on Statutory Corporations, Companies and Other Bodies in Which the Government of India have financial or controlling interestHighlights pertaining to questions of 17th Lok Sabha






Contact Us 
Disclaimer











        Developed and Hosted by National Informatics Centre (NIC)

Content on this website is published,
            managed & maintained by Software Unit, Computer (HW & SW) Management. Branch,
            Lok Sabha Secretariat





HomeMembersBusinessQuestionsDebatesPapers Laid


LegislationCommitteesSANSAD TVIntranetSecretariatPRIDE


RecruitmentSC/ST ReservationConferenceParliament Library


About ParliamentPhoto GalleryRelated LinksRTITendersFAQ


SpeakerDy. SpeakerLeader of the HousePanel of ChairpersonsContact UsFeedback


Council of MinistersPublications of MinistriesParliamentry ProceduresJournal of Parliamentary Information
Visitor's Counter:113191934







Copyright
Privacy Policy
Disclaimer
Terms &
                Conditions

                Accessibility Statement
Accessibility
                Options
Feedback
Site Map







